Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/31412
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHommels, T. M.-
dc.contributor.authorHermanides, R. S.-
dc.contributor.authorRasoul, S.-
dc.contributor.authorBerta, B.-
dc.contributor.authorIJsselmuiden, A. J. J.-
dc.contributor.authorJessurun, G. A. J.-
dc.contributor.authorBENIT, Edouard-
dc.contributor.authorPereira, B.-
dc.contributor.authorDe Luca, G.-
dc.contributor.authorKedhi, E.-
dc.date.accessioned2020-07-06T09:13:02Z-
dc.date.available2020-07-06T09:13:02Z-
dc.date.issued2019-
dc.date.submitted2020-07-06T09:11:36Z-
dc.identifier.citationNetherlands Heart Journal, 27 (11) , p. 541 -549-
dc.identifier.urihttp://hdl.handle.net/1942/31412-
dc.description.abstractBackground Diabetes mellitus (DM) patients show higher rates of repeat revascularisation even in the era of modern drug-eluting stents (DES). The concept of bioresorbable scaffolds is becoming captivating, as it might allow for repeat interventions, prolonging the time span during which patients can be treated by percutaneous coronary intervention (PCI). Aims We intend to evaluate the short- and long-term safety and efficacy of Absorb bioresorbable vascular scaffolds (Absorb BVS) in the treatment of coronary artery disease (CAD) in DM patients for any indication. Methods The ABSORB DM Benelux is an international prospective study in DM patients who have undergone PCI with >= 1 Absorb BVS. Major adverse cardiac events (MACE) at 1 year was the primary endpoint, defined as a composite of all-cause death, any myocardial infarction (MI) and ischaemia-driven target vessel revascularisation (TVR). Secondary endpoints were target lesion failure (TLF) and definite or probable scaffold thrombosis (ScT). Results Between April 2015 and March 2017, 150 DM patients and 188 non-complex lesions were treated. Device implantation was successful in 100%. MACE occurred in 14 (9.5%) patients, with all-cause death occurring in 4 (2.7%), any MI in 6 (4.1%) and ischaemia-driven TVR in 7 (4.8%) respectively. TLF was reported in 11 (7.5%). Definite and probable ScT was observed in 2 (1.4%). Conclusion Absorb BVS for treatment of anatomically low-risk patients with DM show acceptable safety and efficacy outcomes at 1 year. If these promising results are confirmed after a longer follow-up period, new-generation bioresorbable scaffolds combined with refinement of implantation techniques might open new horizons for CAD treatment in DM patients.-
dc.language.isoen-
dc.publisherBOHN STAFLEU VAN LOGHUM BV-
dc.rightsOpen Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.-
dc.subject.otherBioresorbable scaffold; Diabetes mellitus; Coronary artery disease;-
dc.subject.otherPercutaneous coronary intervention; Scaffold thrombosis-
dc.titleThe 1‑year safety and efficacy outcomes of Absorb bioresorbable vascular scaffolds for coronary artery disease treatment in diabetes mellitus patients: the ABSORB DM Benelux study-
dc.typeJournal Contribution-
dc.identifier.epage549-
dc.identifier.issue11-
dc.identifier.spage541-
dc.identifier.volume27-
local.bibliographicCitation.jcatA1-
dc.description.notesHommels, TM (reprint author), Isala Klin, Zwolle, Netherlands.-
dc.description.notest.m.hommels@isala.nl-
local.publisher.placePOSTBUS 246, 3990 GA HOUTEN, NETHERLANDS-
local.type.refereedRefereed-
local.type.specifiedArticle-
local.classIncludeIn-ExcludeFrom-List/ExcludeFromFRIS-
dc.identifier.doi10.1007/s12471-019-1293-7-
dc.identifier.isiWOS:000493609700004-
dc.identifier.eissn-
dc.identifier.eissn1876-6250-
local.provider.typewosris-
item.contributorHommels, T. M.-
item.contributorHermanides, R. S.-
item.contributorRasoul, S.-
item.contributorBerta, B.-
item.contributorIJsselmuiden, A. J. J.-
item.contributorJessurun, G. A. J.-
item.contributorBENIT, Edouard-
item.contributorPereira, B.-
item.contributorDe Luca, G.-
item.contributorKedhi, E.-
item.fullcitationHommels, T. M.; Hermanides, R. S.; Rasoul, S.; Berta, B.; IJsselmuiden, A. J. J.; Jessurun, G. A. J.; BENIT, Edouard; Pereira, B.; De Luca, G. & Kedhi, E. (2019) The 1‑year safety and efficacy outcomes of Absorb bioresorbable vascular scaffolds for coronary artery disease treatment in diabetes mellitus patients: the ABSORB DM Benelux study. In: Netherlands Heart Journal, 27 (11) , p. 541 -549.-
item.accessRightsClosed Access-
item.fulltextWith Fulltext-
crisitem.journal.issn1568-5888-
crisitem.journal.eissn1876-6250-
Appears in Collections:Research publications
Show simple item record

SCOPUSTM   
Citations

1
checked on Sep 7, 2020

WEB OF SCIENCETM
Citations

5
checked on Apr 21, 2024

Page view(s)

34
checked on Sep 7, 2022

Download(s)

2
checked on Sep 7, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.